Scholarlink

<p>Clonal hematopoiesis of indeterminate potential (CHIP) increases with age and has been linked to cardiovascular disease. Apparent treatment-resistant hypertension (aTRH) is a severe, age-associated form of hypertension with poor response to therapy. Here we show that CHIP is enriched in patients with aTRH and is independently associated with poorer treatment response and adverse cardiac remodeling. In a multicenter discovery cohort and two community-based validation cohorts, CHIP was detected in ~23% of patients with aTRH versus ~7% of matched controlled-hypertension controls. CHIP carriers exhibited larger left ventricular dimensions, lower ejection fraction, elevated proinflammatory cytokines, smaller reductions in systolic and diastolic blood pressure after medication intensification and a substantially lower likelihood of achieving clinically controlled aTRH. Higher variant allele fraction and loss-of-function variants were linked to worse outcomes. These results identify CHIP as a common, clinically relevant biomarker in aTRH and suggest that targeting CHIP-related inflammation could improve antihypertensive treatment efficacy and outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clonal hematopoiesis in apparent treatment-resistant hypertension, insights from multiple medical centers and community-based cohorts

  • 期刊论文

  • 发表日期：

    2025年11月24日

查看全文
  • Cheng Lv,
  • Haiyue Wang,
  • Liang Yu,
  • Pengyan Hu,
  • Xiao Xiao,
  • Ruofei Li,
  • Xiayidan Alimu,
  • Yushan Tang,
  • Na Lu,
  • Cunjin Wu,
  • Jun Zheng,
  • Yu Zhang,
  • Rutai Hui,
  • Yibo Wang

摘要

Clonal hematopoiesis of indeterminate potential (CHIP) increases with age and has been linked to cardiovascular disease. Apparent treatment-resistant hypertension (aTRH) is a severe, age-associated form of hypertension with poor response to therapy. Here we show that CHIP is enriched in patients with aTRH and is independently associated with poorer treatment response and adverse cardiac remodeling. In a multicenter discovery cohort and two community-based validation cohorts, CHIP was detected in ~23% of patients with aTRH versus ~7% of matched controlled-hypertension controls. CHIP carriers exhibited larger left ventricular dimensions, lower ejection fraction, elevated proinflammatory cytokines, smaller reductions in systolic and diastolic blood pressure after medication intensification and a substantially lower likelihood of achieving clinically controlled aTRH. Higher variant allele fraction and loss-of-function variants were linked to worse outcomes. These results identify CHIP as a common, clinically relevant biomarker in aTRH and suggest that targeting CHIP-related inflammation could improve antihypertensive treatment efficacy and outcomes.